Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation.
作者信息
Godfrey Catherine, Thigpen Michael C, Crawford Keith W, Jean-Phillippe Patrick, Pillay Deenan, Persaud Deborah, Kuritzkes Daniel R, Wainberg Mark, Raizes Elliot, Fitzgibbon Joseph
机构信息
National Institute of Allergy and Infectious Diseases, National Institutes of Health.
University College London, United Kingdom.
出版信息
J Infect Dis. 2017 Dec 1;216(suppl_9):S798-S800. doi: 10.1093/infdis/jix137.
Abstract
摘要
相似文献
1
Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation.
J Infect Dis. 2017 Dec 1;216(suppl_9):S798-S800. doi: 10.1093/infdis/jix137.
2
HIV resistance and the developing world.
Int J Antimicrob Agents. 2007 May;29(5):510-7. doi: 10.1016/j.ijantimicag.2007.01.003. Epub 2007 Mar 7.
3
The Impact of HIV-1 Drug Escape on the Global Treatment Landscape.
Cell Host Microbe. 2019 Jul 10;26(1):48-60. doi: 10.1016/j.chom.2019.06.010.
4
Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment.
Clin Infect Dis. 2009 May 1;48(9):1318-22. doi: 10.1086/597779.
5
Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
J Infect Dis. 2004 Jul 15;190(2):285-92. doi: 10.1086/422007. Epub 2004 Jun 11.
6
Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing.
AIDS. 2016 Apr 24;30(7):1137-40. doi: 10.1097/QAD.0000000000001033.
7
Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
PLoS One. 2015 Oct 29;10(10):e0141318. doi: 10.1371/journal.pone.0141318. eCollection 2015.
8
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
PLoS One. 2017 Jun 5;12(6):e0178942. doi: 10.1371/journal.pone.0178942. eCollection 2017.
9
Antiretroviral update: recent advances expand options for patients with HIV.
Adv Nurse Pract. 2004 Nov;12(11):53-4, 56.
10
Antiretroviral Drug Resistance Among Children and Youth in the United States With Perinatal HIV.
Clin Infect Dis. 2016 Jul 1;63(1):133-137. doi: 10.1093/cid/ciw213. Epub 2016 Apr 7.
引用本文的文献
1
HIV-1 subtype distribution and drug resistance profiles among PLWHA with detectable viremia in Henan Province, China, 2023.
Sci Rep. 2025 May 22;15(1):17825. doi: 10.1038/s41598-025-02949-1.
2
In Vitro Anti-HIV-1 Activity of Fucoidans from Brown Algae.
Mar Drugs. 2024 Jul 31;22(8):355. doi: 10.3390/md22080355.
3
Strengthening and enhancing national antiretroviral drug resistance surveillance in Zimbabwe-A country that has reached UNAIDS 95-95-95 amongst adults.
Front Public Health. 2024 Feb 14;12:1346027. doi: 10.3389/fpubh.2024.1346027. eCollection 2024.
4
"I can live a normal life": Exploring adherence to antiretroviral therapy in Indonesian adolescents living with HIV.
Belitung Nurs J. 2022 Apr 26;8(2):108-114. doi: 10.33546/bnj.2024. eCollection 2022.
5
Achieving virological control in pan-resistant HIV-1 infection: A case series.
EBioMedicine. 2022 Mar;77:103906. doi: 10.1016/j.ebiom.2022.103906. Epub 2022 Mar 4.
6
First line antiretroviral treatment failure and associated factors among people living with HIV in northwest Ethiopia.
Afr Health Sci. 2021 Mar;21(1):263-272. doi: 10.4314/ahs.v21i1.34.
7
Novel HIV PR inhibitors with C4-substituted bis-THF and bis-fluoro-benzyl target the two active site mutations of highly drug resistant mutant PR.
Biochem Biophys Res Commun. 2021 Aug 20;566:30-35. doi: 10.1016/j.bbrc.2021.05.094. Epub 2021 Jun 7.
8
HIV Drug Resistance in Children and Adolescents: Always a Challenge?
Curr Epidemiol Rep. 2021;8(3):97-107. doi: 10.1007/s40471-021-00268-3. Epub 2021 Mar 18.
9
HIV primary drug resistance and associated HIV risk factors among HIV positive blood donors in Brazil from 2007 to 2017.
Transfus Med. 2021 Apr;31(2):104-112. doi: 10.1111/tme.12766. Epub 2021 Mar 4.
10
Pharmacological activation of the circadian component REV-ERB inhibits HIV-1 replication.
Sci Rep. 2020 Aug 6;10(1):13271. doi: 10.1038/s41598-020-70170-3.
本文引用的文献
1
Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring.
Lancet Infect Dis. 2017 Jan;17(1):e26-e29. doi: 10.1016/S1473-3099(16)30212-2. Epub 2016 Oct 20.
2
Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?
Virol J. 2016 Oct 12;13(1):170. doi: 10.1186/s12985-016-0628-x.
3
SHIVA - a web application for drug resistance and tropism testing in HIV.
BMC Bioinformatics. 2016 Aug 22;17(1):314. doi: 10.1186/s12859-016-1179-2.
4
How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact.
PLoS One. 2016 Jul 8;11(7):e0158620. doi: 10.1371/journal.pone.0158620. eCollection 2016.
5
Near real-time monitoring of HIV transmission hotspots from routine HIV genotyping: an implementation case study.
Lancet HIV. 2016 May;3(5):e231-8. doi: 10.1016/S2352-3018(16)00046-1. Epub 2016 Apr 7.
6
Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure.
Antimicrob Agents Chemother. 2016 May 23;60(6):3380-97. doi: 10.1128/AAC.00038-16. Print 2016 Jun.
7
High Prevalence of HIV Low Abundance Drug-Resistant Variants in a Treatment-Naive Population in North Rift Kenya.
AIDS Res Hum Retroviruses. 2015 Dec;31(12):1274-7. doi: 10.1089/AID.2015.0039. Epub 2015 Oct 8.
8
A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK.
AIDS. 2015 Sep 24;29(15):1917-25. doi: 10.1097/QAD.0000000000000768.
9
Minority drug-resistant HIV-1 variants in treatment naïve East-African and Caucasian patients detected by allele-specific real-time PCR.
PLoS One. 2014 Oct 21;9(10):e111042. doi: 10.1371/journal.pone.0111042. eCollection 2014.
10
Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
N Engl J Med. 2014 Jul 17;371(3):234-47. doi: 10.1056/NEJMoa1311274.
Zotero 插件